2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife data
2022
The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190)
Piedimonte S, Kim S, Clark M, Lheureux S, May T, Bernardini M, Atenafu E. The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190). Gynecologic Oncology 2022, 166: s109. DOI: 10.1016/s0090-8258(22)01417-2.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerAdvanced high-grade serous ovarian cancerPlatinum-free intervalSerous ovarian cancerNeoadjuvant chemotherapyOverall survivalCA 125BRCA statusOvarian cancerHigh CA 125 levelsMedian platinum-free intervalKaplan-Meier survival analysisGrade serous ovarian cancerBaseline CA-125Lower median PFSCA-125 levelsPlatinum-resistant diseasePlatinum-sensitive diseaseRetrospective cohort studyTertiary cancer centerDays of chemotherapySubset of patientsCA 125 valuesBRCA mutation statusSignificant differences
2018
Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer?
Clark M, Lee Y, Xu W, Brown T, May T. Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer? Gynecologic Oncology 2018, 149: 92. DOI: 10.1016/j.ygyno.2018.04.210.Peer-Reviewed Original ResearchAdvanced epithelial ovarian cancerNeoadjuvant chemotherapyOverall survivalOvarian cancerChemotherapySurgeryCancerWomen